Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOPHER MICHAEL PIECZONKA

Allopathic & Osteopathic Physicians Urology

NPI
1376530121
CMS profile
333859
Location
SYRACUSE, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$136,447.53

212 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOPHER MICHAEL PIECZONKA

NPI 1376530121 · CMS profile ID 333859

Allopathic & Osteopathic Physicians / Urology

SYRACUSE, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376530121?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOPHER MICHAEL PIECZONKA, NPI 1376530121, CMS profile ID 333859. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376530121?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHRISTOPHER MICHAEL PIECZONKA, NPI 1376530121, CMS profile ID 333859. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376530121?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHRISTOPHER MICHAEL PIECZONKA, NPI 1376530121, CMS profile ID 333859, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1376530121?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

212 matching records · $136,447.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 212 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 212.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer Healthcare Pharmaceuticals Inc. $1,600.0010/30/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000931825 CMS
Janssen Biotech, Inc. $13.7710/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988382289 CMS
ACCORD HEALTHCARE, INC. $108.0010/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052317065 CMS
Sumitomo Pharma America, Inc. $17.2810/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030805623 CMS
Verity Pharmaceuticals Inc. $17.6210/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019424523 CMS
Myriad Genetic Laboratories, Inc. $14.3610/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059791951 CMS
Myriad Genetic Laboratories, Inc. $143.5610/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059791955 CMS
Dendreon Pharmaceuticals LLC $17.4910/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060289443 CMS
Bayer Healthcare Pharmaceuticals Inc. $68.3810/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000920367 CMS
Boston Scientific Corporation $17.4010/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022424661 CMS
Sumitomo Pharma America, Inc. $132.9610/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030805609 CMS
Sumitomo Pharma America, Inc. $202.3910/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030805627 CMS
Sumitomo Pharma America, Inc. $192.2410/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030805629 CMS
Merck Sharp & Dohme LLC $150.0010/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048545553 CMS
Merck Sharp & Dohme LLC $5,005.0010/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048545559 CMS
Bayer Healthcare Pharmaceuticals Inc. $6,240.0010/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000933503 CMS
Astellas Pharma US Inc $83.9910/05/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034571479 CMS
Astellas Pharma US Inc $69.9910/05/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034571485 CMS
AstraZeneca Pharmaceuticals LP $1,050.0010/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025039259 CMS
Dendreon Pharmaceuticals LLC $22.9210/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060289441 CMS
Ferring Pharmaceuticals Inc. $117.5009/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044224009 CMS
PFIZER INC. $12.8909/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050446255 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.4109/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000840362 CMS
Bayer Healthcare Pharmaceuticals Inc. $188.8009/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000926893 CMS
Merck Sharp & Dohme LLC $47.1409/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048545539 CMS
Merck Sharp & Dohme LLC $51.4309/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048545551 CMS
Merck Sharp & Dohme LLC $34.4509/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048545555 CMS
Merck Sharp & Dohme LLC $25.0009/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048545549 CMS
Merck Sharp & Dohme LLC $371.2109/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048817169 CMS
Bayer Healthcare Pharmaceuticals Inc. $524.7209/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000929691 CMS
Sumitomo Pharma America, Inc. $19.8709/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030805619 CMS
Astellas Pharma US Inc $26.1909/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034517011 CMS
Sun Pharmaceutical Industries Inc. $20.1909/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053818431 CMS
Bayer Healthcare Pharmaceuticals Inc. $73.9409/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000920839 CMS
Bayer Healthcare Pharmaceuticals Inc. $74.9909/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000921105 CMS
Bayer Healthcare Pharmaceuticals Inc. $146.1909/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000925901 CMS
Bayer Healthcare Pharmaceuticals Inc. $7.4609/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000833615 CMS
Bayer Healthcare Pharmaceuticals Inc. $10.4009/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000834873 CMS
Bayer Healthcare Pharmaceuticals Inc. $42.1209/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000919279 CMS
Bayer Healthcare Pharmaceuticals Inc. $301.3009/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000928061 CMS
Bayer Healthcare Pharmaceuticals Inc. $8,320.0009/14/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000933873 CMS
Bayer Healthcare Pharmaceuticals Inc. $315.2209/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000928117 CMS
Dendreon Pharmaceuticals LLC $16.0209/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060289439 CMS
PFIZER INC. $18.1608/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050489279 CMS
Bayer Healthcare Pharmaceuticals Inc. $315.8108/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000928223 CMS
AstraZeneca Pharmaceuticals LP $19.6408/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025071511 CMS
Astellas Pharma US Inc $2,090.0008/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034440017 CMS
Janssen Scientific Affairs, LLC $32.1608/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988525617 CMS
PFIZER INC. $15.3708/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050501811 CMS
Astellas Pharma US Inc $75.0008/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034417673 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $84,051.59 169
PY2020 $64,461.36 103
PY2021 $70,215.75 116
PY2022 $102,735.01 168
PY2023 $136,447.53 212
PY2024 $117,467.19 216
PY2025 $221,773.60 216

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $53,652.45 43
PY2025 Principal investigator $6,436,553.89 492
PY2024 Recipient $3,980.00 2
PY2024 Principal investigator $6,175,115.62 421
PY2023 Recipient $6,643.62 11
PY2023 Principal investigator $3,550,725.72 347
PY2022 Principal investigator $3,987,429.31 448
PY2021 Recipient $897.03 3
PY2021 Principal investigator $3,344,765.27 235
PY2020 Recipient $3,575.77 2
PY2020 Principal investigator $5,032,788.13 326
PY2019 Recipient $2,074.96 1
PY2019 Principal investigator $1,896,669.41 291

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

535 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $10,129.43 12/31/2025 Non-covered Recipient Entity
Associated Medical Professionals URO
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett No dispute reported 06/30/2026 1232925153
Principal investigator 1 Merck Sharp & Dohme LLC $10,076.30 12/31/2025 Non-covered Recipient Entity
Associated Medical Professionals of NY
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 1232926737
Principal investigator 1 Merck Sharp & Dohme LLC $12,322.38 12/31/2025 Non-covered Recipient Entity
Associated Medical Professionals of NY
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 No dispute reported 06/30/2026 1232927929
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,650.83 12/31/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY, PLLC
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190313885
Principal investigator 1 Janssen Research & Development, LLC $6,087.00 12/29/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175336413
Principal investigator 1 Janssen Research & Development, LLC $37,561.00 12/29/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175336820
Principal investigator 1 Janssen Research & Development, LLC $6,346.00 12/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337197
Principal investigator 1 PFIZER INC. $46,207.89 12/25/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228725826
Principal investigator 1 MEDIVATION LLC. $1,443.00 12/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228741077
Principal investigator 1 MEDIVATION LLC. $1,443.00 12/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228747359
Principal investigator 1 MEDIVATION LLC. $1,443.00 12/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228748777
Principal investigator 1 Janssen Research & Development, LLC $3,621.00 12/22/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175336422
Principal investigator 1 Janssen Research & Development, LLC $650.00 12/22/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175336429
Principal investigator 1 Janssen Research & Development, LLC $180.00 12/22/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175336883
Principal investigator 1 Janssen Research & Development, LLC $37,168.00 12/22/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175336994
Principal investigator 1 Sumitomo Pharma America, Inc. $4,350.00 12/22/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657720
Principal investigator 1 Janssen Research & Development, LLC $194.00 12/18/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175336324
Principal investigator 1 Janssen Research & Development, LLC $200.00 12/18/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175337142
Principal investigator 1 Janssen Research & Development, LLC $2,707.00 12/18/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175337188
Principal investigator 1 Janssen Research & Development, LLC $6,266.00 12/18/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175337318
Principal investigator 1 Janssen Research & Development, LLC $2,135.00 12/17/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247807
Principal investigator 1 Janssen Research & Development, LLC $1,570.00 12/16/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247929
Principal investigator 1 Janssen Research & Development, LLC $113,000.00 12/15/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175336455
Principal investigator 1 Janssen Research & Development, LLC $200.00 12/15/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175336517
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 12/15/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175336722
Principal investigator 1 Janssen Research & Development, LLC $5,988.00 12/15/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175337114
Principal investigator 1 Janssen Research & Development, LLC $4,802.00 12/15/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175337181
Principal investigator 1 Janssen Research & Development, LLC $825.00 12/15/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337289
Principal investigator 1 Janssen Research & Development, LLC $7,242.00 12/12/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175337214
Principal investigator 1 Janssen Research & Development, LLC $1,950.00 12/12/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175337496
Principal investigator 1 Janssen Research & Development, LLC $3,077.84 12/09/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247699
Principal investigator 1 Janssen Research & Development, LLC $316.00 12/09/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247985
Principal investigator 1 MEDIVATION LLC. $1,261.00 12/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739447
Principal investigator 1 Janssen Research & Development, LLC $11,202.00 12/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336391
Principal investigator 1 Janssen Research & Development, LLC $12,692.00 12/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336461
Principal investigator 1 Janssen Research & Development, LLC $38,155.00 12/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336526
Principal investigator 1 Janssen Research & Development, LLC $2,718.00 12/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175336534
Principal investigator 1 Janssen Research & Development, LLC $316.00 12/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175336691
Principal investigator 1 Janssen Research & Development, LLC $52,298.00 12/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337365
Principal investigator 1 Janssen Research & Development, LLC $7,632.00 12/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175337374
Principal investigator 1 Janssen Research & Development, LLC $10,500.00 11/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175336250
Principal investigator 1 Janssen Research & Development, LLC $600.00 11/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175336377
Principal investigator 1 Janssen Research & Development, LLC $400.00 11/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175336504
Principal investigator 1 Janssen Research & Development, LLC $200.00 11/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175337326
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $520.00 11/27/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409662
Principal investigator 1 Janssen Research & Development, LLC $8,097.00 11/27/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336231
Principal investigator 1 Janssen Research & Development, LLC $11,394.00 11/26/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175248016
Principal investigator 1 Janssen Research & Development, LLC $550.00 11/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175336275
Principal investigator 1 Janssen Research & Development, LLC $194.00 11/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175336292
Principal investigator 1 Janssen Research & Development, LLC $5,988.00 11/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175337382
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $153,099.65 11/21/2025 Non-covered Recipient Entity
Associated Medical Professionals Of Ny, PLLC
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1235998860
Principal investigator 1 Janssen Research & Development, LLC $13,486.00 11/21/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336208
Principal investigator 1 Janssen Research & Development, LLC $53,304.00 11/21/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336729
Principal investigator 1 Janssen Research & Development, LLC $550.00 11/21/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337097
Principal investigator 1 Janssen Research & Development, LLC $8,270.00 11/21/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337471
Principal investigator 1 Janssen Research & Development, LLC $3,250.00 11/20/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175336856
Principal investigator 1 Janssen Research & Development, LLC $11,976.00 11/20/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175337280
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 11/20/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175337404
Principal investigator 1 Janssen Research & Development, LLC $11,976.00 11/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175336300
Principal investigator 1 Janssen Research & Development, LLC $200.00 11/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175337108
Principal investigator 1 Janssen Research & Development, LLC $550.00 11/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175337242
Principal investigator 1 PFIZER INC. $46,207.89 11/17/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726456
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $1,000.00 11/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY, PLLC
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230648
Principal investigator 1 PFIZER INC. $46,207.89 11/15/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727235
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 11/14/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409854
Principal investigator 1 Janssen Research & Development, LLC $1,570.00 11/14/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247853
Principal investigator 1 Janssen Research & Development, LLC $316.00 11/13/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247758
Principal investigator 1 Janssen Research & Development, LLC $316.00 11/13/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247782
Principal investigator 1 Janssen Research & Development, LLC $3,077.84 11/13/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247831
Principal investigator 1 Janssen Research & Development, LLC $142.00 11/13/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247920
Principal investigator 1 Janssen Research & Development, LLC $3,621.00 11/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175336406
Principal investigator 1 Janssen Research & Development, LLC $8,542.00 11/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175336447
Principal investigator 1 Janssen Research & Development, LLC $25,626.00 11/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175337248
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $812.50 11/12/2025 Non-covered Recipient Entity
Associated Medical Professionals Of NY PLLC Admin
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225419877
Principal investigator 1 Janssen Research & Development, LLC $3,140.00 11/07/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247975
Principal investigator 1 Janssen Research & Development, LLC $9,519.00 11/07/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336397
Principal investigator 1 Dendreon Pharmaceuticals LLC $500.00 11/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892512
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 11/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892540
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 11/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892566
Principal investigator 1 Dendreon Pharmaceuticals LLC $8,520.00 11/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892578
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,920.00 11/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892585
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,970.00 11/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892589
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,970.00 11/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892593
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,920.00 11/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892596
Principal investigator 1 Dendreon Pharmaceuticals LLC $5,720.00 11/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892600
Principal investigator 1 Ferring Pharmaceuticals AS $1,753.50 11/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States No dispute reported 06/30/2026 1242061273
Principal investigator 1 MEDIVATION LLC. $1,443.00 11/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739517
Principal investigator 1 MEDIVATION LLC. $1,261.00 11/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739800
Principal investigator 1 MEDIVATION LLC. $1,443.00 11/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228741009
Principal investigator 1 Sumitomo Pharma America, Inc. $3,246.00 11/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654954
Principal investigator 1 Janssen Research & Development, LLC $3,034.00 11/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175336556
Principal investigator 1 Janssen Research & Development, LLC $316.00 11/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175336578
Principal investigator 1 Janssen Research & Development, LLC $4,005.00 11/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175336599
Principal investigator 1 Janssen Research & Development, LLC $550.00 11/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175337043
Principal investigator 1 Janssen Research & Development, LLC $4,504.00 11/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175337426
Principal investigator 1 Janssen Research & Development, LLC $159.00 11/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175337434
Principal investigator 1 Janssen Research & Development, LLC $17,964.00 10/30/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175336199
Principal investigator 1 Janssen Research & Development, LLC $1,744.00 10/30/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175336354
Principal investigator 1 Janssen Research & Development, LLC $6,787.68 10/28/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247891
Principal investigator 1 Janssen Research & Development, LLC $142.00 10/28/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247913
Principal investigator 1 PFIZER INC. $184,831.55 10/27/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727075
Principal investigator 1 PFIZER INC. $184,831.55 10/26/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727025
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $810.00 10/24/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409978
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,025.00 10/24/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410240
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,500.00 10/24/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410252
Principal investigator 1 Janssen Research & Development, LLC $3,077.84 10/23/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247740
Principal investigator 1 Janssen Research & Development, LLC $948.00 10/23/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247956
Principal investigator 1 Janssen Research & Development, LLC $142.00 10/23/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175248023
Principal investigator 1 Janssen Research & Development, LLC $600.00 10/23/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175337164
Principal investigator 1 Janssen Research & Development, LLC $5,150.00 10/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175337018
Principal investigator 1 MEDIVATION LLC. $300.00 10/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228747906
Principal investigator 1 Janssen Research & Development, LLC $316.00 10/16/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175248066
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 10/15/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410004
Principal investigator 1 Ferring Pharmaceuticals AS $2,630.25 10/14/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States No dispute reported 06/30/2026 1242061163
Principal investigator 1 Janssen Research & Development, LLC $53,304.00 10/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336362
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 10/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336509
Principal investigator 1 Janssen Research & Development, LLC $8,097.00 10/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336750
Principal investigator 1 Janssen Research & Development, LLC $1,983.00 10/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336774
Principal investigator 1 Janssen Research & Development, LLC $3,307.00 10/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336908
Principal investigator 1 Janssen Research & Development, LLC $18,670.00 10/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337035
Principal investigator 1 Janssen Research & Development, LLC $18,733.00 10/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337205
Principal investigator 1 Janssen Research & Development, LLC $11,380.00 10/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337341
Principal investigator 1 Janssen Research & Development, LLC $550.00 10/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337445
Principal investigator 1 Janssen Research & Development, LLC $450.00 10/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175337452
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,812.50 10/10/2025 Non-covered Recipient Entity
Associated Medical Professionals Of NY PLLC Admin
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225419887
Principal investigator 1 Janssen Research & Development, LLC $14,000.00 10/09/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175336760
Principal investigator 1 PFIZER INC. $92,415.77 10/07/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727237
Principal investigator 1 Janssen Research & Development, LLC $25,384.00 10/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336665
Principal investigator 1 PFIZER INC. $92,415.77 10/06/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724926
Principal investigator 1 Janssen Research & Development, LLC $9,569.00 10/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175336939
Principal investigator 1 Janssen Research & Development, LLC $7,632.00 10/02/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175336966
Principal investigator 1 Janssen Research & Development, LLC $900.00 10/02/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175337301
Principal investigator 1 MEDIVATION LLC. $1,261.00 10/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228719587
Principal investigator 1 MEDIVATION LLC. $1,261.00 10/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740818
Principal investigator 1 Celgene Corporation $30,500.00 09/30/2025 Non-covered Recipient Entity
Associated Medical Professionals Of Ny, PLLC
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1222305740
Principal investigator 1 Janssen Research & Development, LLC $7,042.00 09/29/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247790
Principal investigator 1 MEDIVATION LLC. $1,050.00 09/23/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228742864
Principal investigator 1 MEDIVATION LLC. $150.00 09/23/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756595
Principal investigator 1 MEDIVATION LLC. $150.00 09/23/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228757245
Principal investigator 1 Janssen Research & Development, LLC $3,169.00 09/16/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247709
Principal investigator 1 Janssen Research & Development, LLC $632.00 09/16/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247716
Principal investigator 1 Janssen Research & Development, LLC $20,803.00 09/08/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336622
Principal investigator 1 Janssen Research & Development, LLC $4,536.00 09/08/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175336841
Principal investigator 1 Janssen Research & Development, LLC $1,570.00 09/05/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247800
Principal investigator 1 Janssen Research & Development, LLC $12,692.00 09/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336659
Principal investigator 1 MEDIVATION LLC. $1,261.00 09/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755641
Principal investigator 1 MEDIVATION LLC. $1,261.00 09/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755940
Principal investigator 1 MEDIVATION LLC. $1,261.00 09/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756086
Principal investigator 1 Merck Sharp & Dohme LLC $10,245.06 08/31/2025 Non-covered Recipient Entity
Associated Medical Professionals - Urology
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor No dispute reported 06/30/2026 1232930193
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 08/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409222
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 08/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409226
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 08/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409234
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 08/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409268
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 08/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409292
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 08/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409294
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 08/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409426
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 08/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409468
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 08/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409470
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,396.65 08/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409524
Principal investigator 1 Janssen Research & Development, LLC $7,348.00 08/28/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247899
Principal investigator 1 Janssen Research & Development, LLC $4,421.00 08/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175337395
Recipient PFIZER INC. $3,200.00 08/27/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727571
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $1,450.00 08/19/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY, PLLC
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230630
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $3,000.00 08/19/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY, PLLC
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230635
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $15,000.00 08/19/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY, PLLC
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230641
Principal investigator 1 Janssen Research & Development, LLC $3,154.00 08/18/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247825
Principal investigator 1 PFIZER INC. $46,207.89 08/18/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727027
Principal investigator 1 PFIZER INC. $46,207.89 08/17/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228719797
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892396
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892401
Principal investigator 1 Dendreon Pharmaceuticals LLC $7,100.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892405
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892409
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892413
Principal investigator 1 Dendreon Pharmaceuticals LLC $750.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892416
Principal investigator 1 Dendreon Pharmaceuticals LLC $8,520.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892420
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892424
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892428
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892432
Principal investigator 1 Dendreon Pharmaceuticals LLC $7,100.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892446
Principal investigator 1 Dendreon Pharmaceuticals LLC $8,520.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892450
Principal investigator 1 Dendreon Pharmaceuticals LLC $750.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892454
Principal investigator 1 Dendreon Pharmaceuticals LLC $8,600.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892457
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 08/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
PROVONE STUDY No dispute reported 06/30/2026 1247892461
Principal investigator 1 Janssen Research & Development, LLC $2,718.00 08/11/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336368
Principal investigator 1 Janssen Research & Development, LLC $3,482.00 08/11/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336849
Principal investigator 1 PFIZER INC. $138,623.66 08/09/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727165
Principal investigator 1 Janssen Research & Development, LLC $6,346.00 08/07/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336486
Principal investigator 1 Janssen Research & Development, LLC $2,800.00 08/07/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336641
Principal investigator 1 Janssen Research & Development, LLC $200.00 08/07/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175337389
Principal investigator 1 PFIZER INC. $138,623.66 08/07/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727233
Principal investigator 1 Janssen Research & Development, LLC $5,600.00 08/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336571
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $520.00 08/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409284
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $338.00 08/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409356
Principal investigator 1 MEDIVATION LLC. $1,261.00 08/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228743022
Principal investigator 1 MEDIVATION LLC. $1,261.00 08/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755430
Principal investigator 1 MEDIVATION LLC. $1,261.00 08/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756695
Principal investigator 1 MEDIVATION LLC. $1,261.00 08/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756974
Principal investigator 1 MEDIVATION LLC. $1,261.00 08/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228757031
Principal investigator 1 PFIZER INC. $46,207.89 07/29/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726624
Principal investigator 1 Epizyme, Inc. $2,224.80 07/28/2025 Non-covered Recipient Entity
Associated Medical Professionals Of Ny, Pllc
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282140
Principal investigator 1 Epizyme, Inc. $3,337.20 07/28/2025 Non-covered Recipient Entity
Associated Medical Professionals Of Ny, Pllc
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282142
Principal investigator 1 Epizyme, Inc. $1,112.40 07/28/2025 Non-covered Recipient Entity
Associated Medical Professionals Of Ny, Pllc
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282144
Principal investigator 1 Janssen Research & Development, LLC $11,811.00 07/28/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175248085
Principal investigator 1 Janssen Research & Development, LLC $20,380.00 07/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336587
Principal investigator 1 Janssen Research & Development, LLC $33,568.00 07/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336865
Principal investigator 1 Janssen Research & Development, LLC $1,744.00 07/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175337419
Principal investigator 1 PFIZER INC. $46,207.89 07/28/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727163
Principal investigator 1 PFIZER INC. $46,207.89 07/21/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228725824
Principal investigator 1 Janssen Research & Development, LLC $825.00 07/18/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336875
Principal investigator 1 Janssen Research & Development, LLC $24,669.00 07/18/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337478
Principal investigator 1 PFIZER INC. $46,207.89 07/18/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724924
Principal investigator 1 Epizyme, Inc. $1,939.00 07/17/2025 Non-covered Recipient Entity
Associated Medical Professionals Of Ny, Pllc
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282138
Principal investigator 1 Janssen Research & Development, LLC $180.00 07/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175336216
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 07/14/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247840
Recipient PFIZER INC. $330.00 07/11/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727513
Principal investigator 1 PFIZER INC. $46,207.89 07/09/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723780
Principal investigator 1 Sumitomo Pharma America, Inc. $1,617.00 07/09/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640270
Principal investigator 1 PFIZER INC. $46,207.89 07/08/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727073
Principal investigator 1 Janssen Research & Development, LLC $22,211.00 07/07/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336471
Principal investigator 1 Janssen Research & Development, LLC $5,887.00 07/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336182
Principal investigator 1 Janssen Research & Development, LLC $15,307.00 07/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336224
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336437
Principal investigator 1 Janssen Research & Development, LLC $3,077.84 07/01/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247881
Principal investigator 1 MEDIVATION LLC. $1,261.00 07/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228742931
Principal investigator 1 MEDIVATION LLC. $1,261.00 07/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754948
Principal investigator 1 MEDIVATION LLC. $1,261.00 07/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755986
Principal investigator 1 MEDIVATION LLC. $279.50 07/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756458
Principal investigator 1 MEDIVATION LLC. $279.50 07/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756816
Principal investigator 1 MEDIVATION LLC. $1,261.00 07/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756862
Principal investigator 1 MEDIVATION LLC. $279.50 07/01/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228757234
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $520.00 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute LLC
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408294
Principal investigator 1 Janssen Research & Development, LLC $45,516.00 06/30/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336826
Principal investigator 1 Janssen Research & Development, LLC $4,360.00 06/27/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175336174
Principal investigator 1 Janssen Research & Development, LLC $165.00 06/25/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175248058
Recipient Dendreon Pharmaceuticals LLC $500.00 06/24/2025 Covered Recipient Physician ProvONE No dispute reported 06/30/2026 1247891628
Recipient Dendreon Pharmaceuticals LLC $250.00 06/24/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891631
Principal investigator 1 Janssen Research & Development, LLC $954.00 06/23/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175337525
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 06/18/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176636392
Principal investigator 1 Sumitomo Pharma America, Inc. $2,000.00 06/18/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176636396
Principal investigator 1 Janssen Research & Development, LLC $1,572.00 06/16/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175254973
Principal investigator 1 Janssen Research & Development, LLC $15,264.00 06/16/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175337149
Principal investigator 1 Janssen Research & Development, LLC $18,204.00 06/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175336889
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 06/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175337081
Principal investigator 1 Janssen Research & Development, LLC $4,112.00 06/09/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247684
Principal investigator 1 Janssen Research & Development, LLC $3,250.00 06/09/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336315
Principal investigator 1 Janssen Research & Development, LLC $22,211.00 06/09/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337089
Principal investigator 1 Janssen Research & Development, LLC $7,632.00 06/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175336681
Principal investigator 1 Janssen Research & Development, LLC $34,179.00 06/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175337272
Recipient Dendreon Pharmaceuticals LLC $500.00 06/05/2025 Covered Recipient Physician ProvONE No dispute reported 06/30/2026 1247891480
Recipient Dendreon Pharmaceuticals LLC $2,130.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891484
Recipient Dendreon Pharmaceuticals LLC $322.73 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891488
Recipient Dendreon Pharmaceuticals LLC $2,130.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891492
Recipient Dendreon Pharmaceuticals LLC $322.73 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891496
Recipient Dendreon Pharmaceuticals LLC $322.73 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891500
Recipient Dendreon Pharmaceuticals LLC $322.73 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891504
Recipient Dendreon Pharmaceuticals LLC $8,520.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891508
Recipient Dendreon Pharmaceuticals LLC $1,242.50 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891511
Recipient Dendreon Pharmaceuticals LLC $4,970.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891514
Recipient Dendreon Pharmaceuticals LLC $2,130.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891518
Recipient Dendreon Pharmaceuticals LLC $101.43 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891523
Recipient Dendreon Pharmaceuticals LLC $473.33 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891526
Recipient Dendreon Pharmaceuticals LLC $322.73 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891530
Recipient Dendreon Pharmaceuticals LLC $101.43 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891534
Recipient Dendreon Pharmaceuticals LLC $101.43 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891539
Recipient Dendreon Pharmaceuticals LLC $322.73 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891543
Recipient Dendreon Pharmaceuticals LLC $1,014.29 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891546
Recipient Dendreon Pharmaceuticals LLC $473.33 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891550
Recipient Dendreon Pharmaceuticals LLC $1,242.50 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891554
Recipient Dendreon Pharmaceuticals LLC $1,242.50 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891558
Recipient Dendreon Pharmaceuticals LLC $1,420.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891562
Recipient Dendreon Pharmaceuticals LLC $101.43 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891567
Recipient Dendreon Pharmaceuticals LLC $101.43 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891570
Recipient Dendreon Pharmaceuticals LLC $101.43 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891574
Recipient Dendreon Pharmaceuticals LLC $1,420.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891578
Recipient Dendreon Pharmaceuticals LLC $322.73 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891581
Recipient Dendreon Pharmaceuticals LLC $4,970.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891585
Recipient Dendreon Pharmaceuticals LLC $1,014.29 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891589
Recipient Dendreon Pharmaceuticals LLC $473.33 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891593
Recipient Dendreon Pharmaceuticals LLC $1,242.50 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891596
Recipient Dendreon Pharmaceuticals LLC $250.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891600
Recipient Dendreon Pharmaceuticals LLC $473.33 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891606
Recipient Dendreon Pharmaceuticals LLC $1,460.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891610
Recipient Dendreon Pharmaceuticals LLC $101.43 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891614
Recipient Dendreon Pharmaceuticals LLC $5,720.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891618
Recipient Dendreon Pharmaceuticals LLC $1,460.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891622
Recipient Dendreon Pharmaceuticals LLC $101.43 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891626
Principal investigator 1 Dendreon Pharmaceuticals LLC $6,390.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247891946
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247891950
Principal investigator 1 Dendreon Pharmaceuticals LLC $6,390.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247891974
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247891978
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247891982
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247891986
Principal investigator 1 Dendreon Pharmaceuticals LLC $8,520.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247891990
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,970.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247891994
Principal investigator 1 Dendreon Pharmaceuticals LLC $9,940.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247891998
Principal investigator 1 Dendreon Pharmaceuticals LLC $6,390.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892002
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892007
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,840.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892011
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892014
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892019
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892022
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892026
Principal investigator 1 Dendreon Pharmaceuticals LLC $7,100.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892030
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,840.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892034
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,970.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892038
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,970.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892042
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,260.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892047
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892050
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892057
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892062
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,260.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892066
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892069
Principal investigator 1 Dendreon Pharmaceuticals LLC $9,940.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892074
Principal investigator 1 Dendreon Pharmaceuticals LLC $7,100.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892077
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,840.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892080
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,970.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892084
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,840.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892087
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,920.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892095
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892099
Principal investigator 1 Dendreon Pharmaceuticals LLC $5,720.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892116
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,920.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892130
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,420.00 06/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
ProvONE No dispute reported 06/30/2026 1247892177
Principal investigator 1 Janssen Research & Development, LLC $3,482.00 06/02/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m No dispute reported 06/30/2026 1175336338
Principal investigator 1 Janssen Research & Development, LLC $8,314.00 05/30/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175336916
Principal investigator 1 PFIZER INC. $46,206.12 05/30/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754443
Principal investigator 1 PFIZER INC. $46,206.12 05/29/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753918
Principal investigator 1 PFIZER INC. $46,207.89 05/29/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754300
Principal investigator 1 Janssen Research & Development, LLC $6,787.68 05/27/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247938
Principal investigator 1 Janssen Research & Development, LLC $142.00 05/27/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247994
Principal investigator 1 Janssen Research & Development, LLC $318.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336191
Principal investigator 1 Janssen Research & Development, LLC $12,015.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336478
Principal investigator 1 Janssen Research & Development, LLC $15,264.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175336649
Principal investigator 1 Janssen Research & Development, LLC $159.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336716
Principal investigator 1 Janssen Research & Development, LLC $142.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175337054
Principal investigator 1 Janssen Research & Development, LLC $865.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175337229
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175337296
Principal investigator 1 Janssen Research & Development, LLC $20,600.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175337463
Principal investigator 1 Janssen Research & Development, LLC $3,034.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175337489
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228722572
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228722968
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778808
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228780857
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790214
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790940
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791065
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791186
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791335
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791376
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791499
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791650
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792106
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792355
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792526
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792952
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793001
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793171
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793236
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793284
Principal investigator 1 MEDIVATION LLC. $279.50 05/26/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793989
Principal investigator 1 Janssen Research & Development, LLC $200.00 05/23/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336675
Principal investigator 1 Janssen Research & Development, LLC $200.00 05/23/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175337265
Principal investigator 1 PFIZER INC. $138,618.36 05/20/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752644
Principal investigator 1 Janssen Research & Development, LLC $33,596.00 05/19/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336239
Principal investigator 1 Janssen Research & Development, LLC $27,517.00 05/19/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336266
Principal investigator 1 Janssen Research & Development, LLC $18,114.00 05/19/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336615
Principal investigator 1 Janssen Research & Development, LLC $5,263.00 05/19/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337002
Principal investigator 1 Janssen Research & Development, LLC $492.00 05/19/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337235
Principal investigator 1 PFIZER INC. $138,618.36 05/19/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723260
Principal investigator 1 PFIZER INC. $138,623.67 05/19/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228759343
Principal investigator 1 Janssen Research & Development, LLC $3,142.00 05/16/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175248073
Principal investigator 1 Janssen Research & Development, LLC $200.00 05/16/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336950
Principal investigator 1 Janssen Research & Development, LLC $3,250.00 05/16/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175337541
Principal investigator 1 Ferring Pharmaceuticals AS $4,773.25 05/15/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States No dispute reported 06/30/2026 1242060287
Principal investigator 1 Janssen Research & Development, LLC $500.00 05/13/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175248046
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228752599
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 05/12/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175336258
Principal investigator 1 Janssen Research & Development, LLC $1,650.00 05/12/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336345
Principal investigator 1 Janssen Research & Development, LLC $9,569.00 05/12/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336542
Principal investigator 1 Janssen Research & Development, LLC $26,652.00 05/12/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336799
Principal investigator 1 PFIZER INC. $46,206.12 05/12/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751771
Principal investigator 1 PFIZER INC. $46,206.12 05/09/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751775
Principal investigator 1 PFIZER INC. $46,207.89 05/09/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754298
Principal investigator 1 Janssen Research & Development, LLC $158.00 05/08/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247733
Principal investigator 1 Janssen Research & Development, LLC $3,393.84 05/08/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247767
Principal investigator 1 Janssen Research & Development, LLC $6,338.00 05/08/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247861
Principal investigator 1 Janssen Research & Development, LLC $948.00 05/08/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247868
Principal investigator 1 Janssen Research & Development, LLC $142.00 05/08/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175248009
Principal investigator 1 Janssen Research & Development, LLC $275.00 05/08/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175248031
Principal investigator 1 Sumitomo Pharma America, Inc. $786.00 05/07/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634277
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228722906
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724368
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724512
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228780061
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789818
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789826
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789895
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790599
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790711
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790766
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790836
Principal investigator 1 MEDIVATION LLC. $1,261.00 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791504
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793017
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793272
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793277
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793317
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793511
Principal investigator 1 MEDIVATION LLC. $279.50 05/05/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793515
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,772.47 04/30/2025 Non-covered Recipient Entity
ASSOCIATE MEDICAL PROFESSIONALS LLC
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1185546945
Principal investigator 1 PFIZER INC. $46,206.12 04/30/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753710
Principal investigator 1 PFIZER INC. $46,206.12 04/29/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752043
Principal investigator 1 PFIZER INC. $46,207.89 04/29/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755973
Principal investigator 1 Janssen Research & Development, LLC $4,716.00 04/28/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247726
Principal investigator 1 Janssen Research & Development, LLC $29,055.00 04/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336933
Principal investigator 1 Janssen Research & Development, LLC $3,173.00 04/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337310
Principal investigator 1 Janssen Research & Development, LLC $18,757.00 04/25/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336609
Principal investigator 1 Janssen Research & Development, LLC $22,246.00 04/24/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175255046
Principal investigator 1 PFIZER INC. $46,206.12 04/21/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752856
Principal investigator 1 PFIZER INC. $46,206.12 04/19/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752320
Principal investigator 1 PFIZER INC. $46,207.89 04/19/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755977
Principal investigator 1 Merck Sharp & Dohme LLC $2,500.00 04/11/2025 Non-covered Recipient Entity
Associated Medical Professionals of NY
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 1232926735
Principal investigator 1 Sumitomo Pharma America, Inc. $3,930.00 04/09/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632896
Principal investigator 1 Sumitomo Pharma America, Inc. $18,951.00 04/09/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632919
Principal investigator 1 Janssen Research & Development, LLC $7,499.00 04/07/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336549
Principal investigator 1 Janssen Research & Development, LLC $31,782.00 04/07/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336785
Principal investigator 1 Janssen Research & Development, LLC $11,533.00 04/04/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175248001
Principal investigator 1 Janssen Research & Development, LLC $15,243.00 04/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336308
Principal investigator 1 Janssen Research & Development, LLC $2,616.00 03/31/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175337172
Principal investigator 1 Janssen Research & Development, LLC $6,703.00 03/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175337257
Principal investigator 1 Janssen Research & Development, LLC $275.00 03/21/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336697
Principal investigator 1 Janssen Research & Development, LLC $400.00 03/21/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336767
Principal investigator 1 Janssen Research & Development, LLC $450.00 03/21/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336980
Principal investigator 1 Janssen Research & Development, LLC $3,200.00 03/21/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175337412
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,193.24 03/19/2025 Non-covered Recipient Entity
ASSOCIATE MEDICAL PROFESSIONALS LLC
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) No dispute reported 06/30/2026 1185546943
Principal investigator 1 Janssen Research & Development, LLC $2,135.00 03/17/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175254888
Principal investigator 1 Janssen Research & Development, LLC $1,113.00 03/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336707
Principal investigator 1 Janssen Research & Development, LLC $159.00 03/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336743
Principal investigator 1 Janssen Research & Development, LLC $316.00 03/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336810
Principal investigator 1 Janssen Research & Development, LLC $550.00 03/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175337121
Principal investigator 1 Janssen Research & Development, LLC $3,034.00 03/13/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175337512
Principal investigator 1 AstraZeneca Pharmaceuticals LP $437,962.70 03/12/2025 Non-covered Recipient Entity
ASSOCIATE MEDICAL PROFESSIONALS LLC
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185546939
Principal investigator 1 Janssen Research & Development, LLC $8,700.00 03/11/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247816
Principal investigator 1 PFIZER INC. $46,206.12 03/11/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754439
Principal investigator 1 Janssen Research & Development, LLC $6,500.00 03/10/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336157
Principal investigator 1 Janssen Research & Development, LLC $550.00 03/10/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336383
Principal investigator 1 Janssen Research & Development, LLC $16,812.00 03/10/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336833
Principal investigator 1 Janssen Research & Development, LLC $1,400.00 03/10/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336986
Principal investigator 1 Janssen Research & Development, LLC $1,910.00 03/10/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175337532
Principal investigator 1 PFIZER INC. $46,206.12 03/10/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753426
Principal investigator 1 PFIZER INC. $46,207.89 03/10/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754605
Principal investigator 1 Janssen Research & Development, LLC $15,940.00 03/07/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337334
Principal investigator 1 Janssen Research & Development, LLC $2,718.00 03/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175336735
Principal investigator 1 Janssen Research & Development, LLC $1,730.00 03/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175337009
Principal investigator 1 Janssen Research & Development, LLC $12,015.00 03/06/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175337520
Principal investigator 1 Janssen Research & Development, LLC $3,169.00 03/03/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247750
Principal investigator 1 Janssen Research & Development, LLC $14,485.00 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336564
Principal investigator 1 Janssen Research & Development, LLC $1,744.00 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175336634
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228720119
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774111
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774319
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774581
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774622
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774709
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774743
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775001
Principal investigator 1 MEDIVATION LLC. $1,261.00 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775029
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775290
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775489
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775753
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775870
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776065
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776789
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777749
Principal investigator 1 MEDIVATION LLC. $1,261.00 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777759
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778042
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778100
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786063
Principal investigator 1 MEDIVATION LLC. $1,261.00 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786088
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786933
Principal investigator 1 MEDIVATION LLC. $279.50 03/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228787233
Principal investigator 1 Janssen Research & Development, LLC $13,924.00 02/28/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336332
Principal investigator 1 Janssen Research & Development, LLC $550.00 02/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336151
Principal investigator 1 Janssen Research & Development, LLC $400.00 02/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336900
Principal investigator 1 Janssen Research & Development, LLC $142.00 02/21/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247773
Principal investigator 1 Janssen Research & Development, LLC $16,110.00 02/21/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247947
Principal investigator 1 Janssen Research & Development, LLC $6,500.00 02/21/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247966
Principal investigator 1 Janssen Research & Development, LLC $632.00 02/21/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175248039
Principal investigator 1 Janssen Research & Development, LLC $8,750.00 02/21/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175255070
Principal investigator 1 PFIZER INC. $138,618.36 02/19/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751592
Principal investigator 1 PFIZER INC. $138,618.36 02/18/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753915
Principal investigator 1 PFIZER INC. $138,623.67 02/18/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755697
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 02/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336793
Principal investigator 1 Janssen Research & Development, LLC $173.00 02/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175336958
Principal investigator 1 Janssen Research & Development, LLC $7,632.00 02/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175337027
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 02/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175337063
Principal investigator 1 Janssen Research & Development, LLC $7,632.00 02/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175337074
Principal investigator 1 Janssen Research & Development, LLC $15,264.00 02/17/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175337503
Principal investigator 1 Janssen Research & Development, LLC $17,150.00 02/13/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175247845
Principal investigator 1 PFIZER INC. $4,957.83 02/12/2025 Non-covered Recipient Entity
Associated Medical Professionals of NY PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228750332
Principal investigator 1 Janssen Research & Development, LLC $3,551.84 02/11/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175248090
Principal investigator 1 Janssen Research & Development, LLC $34,895.00 02/10/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175337222
Principal investigator 1 Janssen Research & Development, LLC $59,843.00 02/10/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175337349
Principal investigator 1 PFIZER INC. $46,206.12 02/10/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753590
Principal investigator 1 PFIZER INC. $46,206.12 02/08/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753131
Principal investigator 1 PFIZER INC. $46,207.89 02/08/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754368
Principal investigator 1 AstraZeneca UK Limited $70,643.99 02/05/2025 Non-covered Recipient Entity
ASSOCIATE MEDICAL PROFESSIONALS LLC
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA) No dispute reported 06/30/2026 1185546941
Principal investigator 1 MEDIVATION LLC. $1,261.00 02/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724534
Principal investigator 1 MEDIVATION LLC. $1,261.00 02/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774352
Principal investigator 1 MEDIVATION LLC. $150.00 02/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774509
Principal investigator 1 MEDIVATION LLC. $1,261.00 02/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774812
Principal investigator 1 MEDIVATION LLC. $150.00 02/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775022
Principal investigator 1 MEDIVATION LLC. $1,261.00 02/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775285
Principal investigator 1 MEDIVATION LLC. $150.00 02/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776458
Principal investigator 1 MEDIVATION LLC. $1,261.00 02/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776462
Principal investigator 1 MEDIVATION LLC. $150.00 02/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776939
Principal investigator 1 MEDIVATION LLC. $750.00 02/04/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786057
Principal investigator 1 Janssen Research & Development, LLC $250.00 02/03/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175255004
Principal investigator 1 Janssen Research & Development, LLC $865.00 02/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175336284
Principal investigator 1 Janssen Research & Development, LLC $7,418.00 02/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175336923
Principal investigator 1 Janssen Research & Development, LLC $18,638.00 02/03/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175337357
Principal investigator 1 PFIZER INC. $92,412.24 01/30/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753714
Principal investigator 1 PFIZER INC. $92,412.24 01/29/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754035
Principal investigator 1 PFIZER INC. $92,415.78 01/29/2025 Non-covered Recipient Entity
Associated Medical Professionals of New York
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755288
Principal investigator 1 Sumitomo Pharma America, Inc. $1,213.20 01/29/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176624925
Principal investigator 1 Janssen Research & Development, LLC $10,631.00 01/28/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175247691
Principal investigator 1 Janssen Research & Development, LLC $10,882.00 01/27/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175336498
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336165
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175336973
Principal investigator 1 Janssen Research & Development, LLC $3,250.00 01/24/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175337157
Principal investigator 1 Janssen Research & Development, LLC $6,365.00 01/14/2025 Non-covered Recipient Entity
Assocd Medcl Professionals Of Ny Pllc Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175254966
Principal investigator 1 Epizyme, Inc. $1,550.64 01/08/2025 Non-covered Recipient Entity
Associated Medical Professionals Of Ny, Pllc
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282136
Principal investigator 1 Janssen Research & Development, LLC $50,975.00 01/02/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175337132
Principal investigator 1 MEDIVATION LLC. $1,261.00 01/02/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775734
Principal investigator 1 MEDIVATION LLC. $1,261.00 01/02/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776015
Principal investigator 1 MEDIVATION LLC. $1,443.00 01/02/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776525
Principal investigator 1 MEDIVATION LLC. $1,261.00 01/02/2025 Non-covered Recipient Entity
ASSOCIATED MEDICAL PROFESSIONALS OF NY
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228785604